Switching Anticoagulants After Breakthrough Stroke Shows No Short-Term Benefit
Overview
In patients with atrial fibrillation experiencing ischemic stroke despite uninterrupted direct oral anticoagulant (DOAC) therapy, switching anticoagulants did not improve 90-day outcomes compared to continuing the same DOAC. Event rates for recurrent stroke, bleeding, and mortality were similar between those who switched therapy and those who did not.
Background
Oral anticoagulants are standard for stroke prevention in atrial fibrillation, but some patients experience breakthrough ischemic strokes despite adherence. Clinicians often consider switching anticoagulants to reduce residual cardioembolic risk. However, evidence regarding the benefit of switching therapy after breakthrough stroke remains limited. This study aimed to evaluate whether changing anticoagulant therapy improves short-term clinical outcomes.
Data Highlights
| Outcome | Switched Therapy (n=543) | Continued Same DOAC (n=463) |
|---|---|---|
| 90-day net clinical benefit (recurrent ischemic stroke + moderate/severe bleeding) | 5% | 5% |
| Recurrent ischemic stroke | ~3% | ~3% |
| Symptomatic intracerebral hemorrhage | ~1% | ~1% |
| Moderate to severe bleeding | Low rates | Low rates |
| All-cause mortality | 8.7% | 9.3% |
| Vascular death | 4.9% | 4.4% |
Key Findings
- Switching anticoagulants after breakthrough ischemic stroke did not reduce 90-day composite outcomes compared to continuing the same DOAC.
- Recurrent ischemic stroke and symptomatic intracerebral hemorrhage rates were approximately equal (~3% and ~1%, respectively) in both groups.
- Noninferiority was demonstrated for the primary composite outcome but not for broader ischemic events or mortality due to wide confidence intervals.
- Switching between DOACs with different mechanisms of action did not improve outcomes, challenging assumptions about mechanistic switching.
- Switching from DOAC to vitamin K antagonists showed suggestive but inconclusive benefits due to small sample size.
- Excluding patients with non-cardioembolic stroke etiologies did not alter results, supporting robustness.
Clinical Implications
Routine switching of anticoagulant therapy solely due to breakthrough ischemic stroke may not confer additional short-term benefit when patients are adherent to uninterrupted DOAC treatment. Clinical decisions to switch should consider factors such as medication adherence, drug interactions, or alternative stroke mechanisms rather than default protocol changes. These findings support continuing current anticoagulation in stable patients after breakthrough events.
Conclusion
This multicenter cohort study suggests no clinically meaningful short-term advantage in switching anticoagulants after breakthrough ischemic stroke in atrial fibrillation patients on DOACs. Continuation of the same anticoagulant remains a reasonable strategy absent other clinical indications.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
